Charles Schwab Investment Management Inc. Purchases 27,927 Shares of ICU Medical, Inc. (NASDAQ:ICUI)

Charles Schwab Investment Management Inc. grew its holdings in ICU Medical, Inc. (NASDAQ:ICUI) by 10.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 301,107 shares of the medical instruments supplier’s stock after acquiring an additional 27,927 shares during the period. Charles Schwab Investment Management Inc.’s holdings in ICU Medical were worth $54,868,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the stock. Hexagon Capital Partners LLC raised its position in ICU Medical by 162.7% during the third quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 122 shares during the period. Allworth Financial LP boosted its holdings in shares of ICU Medical by 100.0% in the third quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 100 shares during the period. Innealta Capital LLC purchased a new position in shares of ICU Medical during the second quarter valued at $32,000. Venturi Wealth Management LLC increased its position in ICU Medical by 1,510.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 322 shares of the medical instruments supplier’s stock valued at $59,000 after purchasing an additional 302 shares during the period. Finally, Russell Investments Group Ltd. lifted its position in shares of ICU Medical by 46.4% in the 1st quarter. Russell Investments Group Ltd. now owns 546 shares of the medical instruments supplier’s stock worth $59,000 after purchasing an additional 173 shares during the period. 96.10% of the stock is owned by hedge funds and other institutional investors.

ICU Medical Stock Performance

NASDAQ ICUI opened at $163.96 on Friday. ICU Medical, Inc. has a fifty-two week low of $83.26 and a fifty-two week high of $196.26. The firm has a market capitalization of $4.01 billion, a P/E ratio of -35.88 and a beta of 0.66. The stock’s fifty day moving average is $174.60 and its two-hundred day moving average is $147.08. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29.

Insiders Place Their Bets

In other news, COO Christian B. Voigtlander sold 1,430 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $158.00, for a total value of $225,940.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $163.46, for a total value of $1,961,520.00. Following the completion of the transaction, the chief executive officer now owns 104,593 shares of the company’s stock, valued at approximately $17,096,771.78. This trade represents a 10.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 40,364 shares of company stock valued at $6,876,478 over the last quarter. 6.70% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Jefferies Financial Group initiated coverage on ICU Medical in a research report on Monday, October 14th. They issued a “hold” rating and a $183.00 price objective for the company. KeyCorp raised their price objective on ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 13th. Raymond James increased their price target on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a report on Thursday, September 12th. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a research note on Wednesday, November 13th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $173.00.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.